Izhodišča: Metformin je peroralni antidiabetik in je po slovenskih smernicah zdravilo prve izbire za zdravljenje sladkorne bolezni tipa 2 (SB2). Svoje mesto si utira tudi pri zdravljenju sindroma policističnih jajčnikov (PCOS), čeprav PCOS (še) ni uradno med indikacijami za zdravljenje z metforminom. Študije kažejo, da metformin izboljša klinično in biokemično sliko PCOS ter zveča stopnjo ovulacije in s tem verjetnost za zanositev pri ženskah s tem sindromom. Farmakološki učinki metformina se ob enakem režimu odmerjanja med bolniki razlikujejo, kar poskušamo med drugim razložiti tudi z vplivom polimorfnih različic v genih, povezanih s farmakodinamiko in farmakokinetiko metformina.
Zaključki: Rezultati raziskav kažejo, da polimorfne različice v genih, povezanih s farmakodinamiko in farmakokinetiko metformina, lahko prispevajo k raznolikosti v odzivu na zdravljenje z metforminom tako pri bolnikih s SB2 kot pri bolnicah s PCOS.Background: According to the Slovenian guidelines, metformin, an oral antidiabetic drug, is a drug of choice for the treatment of type 2 diabetes. Additionally, metformin is paving its way in polycystic ovary syndrome (PCOS) treatment, although the drug has not (yet) been officially indicated to treat PCOS. Studies have shown that metformin improves clinical and biochemical features of PCOS as well as the rate of ovulation and consequently the likelihood of conception in PCOS women. At the same dosage regimen, pharmacological effects of metformin show interindividual variability in metformin responseefforts have been made to at least partly explain the variability with polymorphic variants in genes related to metformin pharmacodynamics and pharmacokinetics.
Conclusions: The results of the current studies indicate that polymorphic variants in genes related to metformin pharmacodynamics and pharmacokinetics may contribute to the interindividual variability in pharmacological response to metformin treatment in diabetic as well as in PCOS patients